Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Research to investigate and improve patient adherence to prescription drug therapies

CVS Caremark is sponsoring research to investigate patient adherence to prescription drug therapies and identify ways to increase adherence. Working with researchers from Harvard and Brigham and Women's Hospital, the company expects knowledge gained from the research will help health professionals better understand patient behavior and lead to developing programs that health care providers and pharmacies can use to improve medication adherence and ultimately help improve patient care and medical outcomes by avoiding costly hospital treatment.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Medtronic, Inc., announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system.

14 Oct 2009

Underwriters exercise their over-allotment option in purchasing additional Stereotaxis' shares

Stereotaxis, Inc. announced today that the underwriters for the recently announced public offering of Stereotaxis common stock have exercised in full their over-allotment option to purchase an additional 975,000 shares of the Company's common stock. The 7,475,000 shares of Stereotaxis common stock in the offering, including the 975,000 shares subject to the over-allotment option, are being sold at a price to the public of $4.00 per share.

12 Oct 2009

Stereotaxis to offer 6,500,000 shares to the public at $4.00 per share

Stereotaxis, Inc. announced today that it had priced the public offering of 6,500,000 shares of its common at a price to the public of $4.00 per share. Stereotaxis has granted the underwriters of the offering an option to purchase up to an additional 975,000 shares of common stock to cover over-allotments, if any. All of the shares in the offering are being offered by Stereotaxis. Stereotaxis expects the offering to close on October 15, 2009.

9 Oct 2009

Stereotaxis receives commitment letter from Silicon Valley Bank

Stereotaxis, Inc. today announced that it has received a commitment letter from Silicon Valley Bank, a member company of SVB Financial Group (Nasdaq: SIVB), to increase and extend its credit facility.

7 Oct 2009

Award-winning GWTG hospitals have lower mortality rates for heart attack and heart failure patients: Study

Hospitals receiving performance awards from the American Heart Association's Get With The Guidelines (GWTG) quality improvement initiative have lower mortality rates for heart attack and heart failure patients than all other hospitals, according to a new study.

7 Oct 2009

Gene therapy to improve ailing heart's contractions of muscle cells

Scientists from the Universities of Michigan and Minnesota show in a research report published online in the FASEB Journal (http://www.fasebj.org) that gene therapy may be used to improve an ailing heart's ability to contract properly. In addition to showing gene therapy's potential for reversing the course of heart failure, it also offers a tantalizing glimpse of a day when "closed heart surgery" via gene therapy is as commonly prescribed as today's cocktail of drugs.

6 Oct 2009

ALL initiative three-year clinical observational study results published

A program that bundled two generic, low-cost drugs - a cholesterol-lowering statin and a blood pressure-lowering drug - and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care.

3 Oct 2009

Cost-effective screening test for coronary artery disease

A simple, non-invasive test appears to be an effective screening tool for identifying patients with silent heart disease who are at risk for a heart attack or sudden death.

1 Oct 2009

Cordis Corporation, Boston Scientific enter agreement to resolve Palmaz infringement suit

Cordis Corporation (“Cordis”) announced today that it has reached an agreement with Boston Scientific (“Boston”) resolving its Palmaz infringement suit relating to Boston’s NIR stent, settling several other cardiology-related cases relating to patents in the Ding, Kastenhofer, Palmaz, and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties.

30 Sep 2009

$10 million grant to Weill Cornell Institute from NIMH to study geriatric depression

The Weill Cornell Institute of Geriatric Psychiatry at NewYork-Presbyterian Hospital/Westchester Division announced today it has received the largest grant in its 20-year history. One of a handful awarded nationally, the new $10 million, five-year "Center Grant" from the National Institute of Mental Health (NIMH) will enable NewYork-Presbyterian/Weill Cornell investigators to advance their pioneering work in understanding the biological, medical, cognitive and psychosocial problems of depressed seniors.

25 Sep 2009

PROSPECT clinical trial results announced

Abbott today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial.

25 Sep 2009

Stereotaxis showcases its remote magnetic navigation technology at TCT symposium

Stereotaxis, Inc. is showcasing the value of its technologies for interventional procedures at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Francisco this week.

24 Sep 2009

Everolimus-eluting stent efficient in treating native coronary artery lesions

Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

24 Sep 2009

$Cardiogenesis sponsors educational symposium on refractory angina treatment method$

Cardiogenesis sponsors educational symposium on refractory angina treatment method

Cardiogenesis Corporation, a market leader in laser transmyocardial revascularization (TMR), today announced that it sponsored an educational symposium yesterday in conjunction with the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.

24 Sep 2009

COMPARE trial results demonstrate higher efficacy of XIENCE V stent system

Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS).

24 Sep 2009

SPIRIT IV trial data demonstrates superior efficacy of XIENCE V stent system

Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.

24 Sep 2009

Cambridge Heart's modified Alternans technology to identify myocardial ischemia

Cambridge Heart, Inc. announced today that it intends to pursue research and development efforts on a new application derived from its core Microvolt T-Wave Alternans (MTWA) technology.

24 Sep 2009

St. Jude Medical's cardiovascular healthcare portfolio to be presented at TCT meeting

St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the company’s portfolio of solutions for cardiovascular healthcare professionals at the 21st annual Transcatheter Cardiovascular Therapeutics meeting in San Francisco. The featured products reflect the company’s continued commitment to developing comprehensive, high-performance solutions which advance the practice of interventional cardiology by improving efficiencies and giving physicians more control.

23 Sep 2009

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Research to investigate and improve patient adherence to prescription drug therapies

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Underwriters exercise their over-allotment option in purchasing additional Stereotaxis' shares

Stereotaxis to offer 6,500,000 shares to the public at $4.00 per share

Stereotaxis receives commitment letter from Silicon Valley Bank

Award-winning GWTG hospitals have lower mortality rates for heart attack and heart failure patients: Study

Gene therapy to improve ailing heart's contractions of muscle cells

ALL initiative three-year clinical observational study results published

Cost-effective screening test for coronary artery disease

Cordis Corporation, Boston Scientific enter agreement to resolve Palmaz infringement suit

$10 million grant to Weill Cornell Institute from NIMH to study geriatric depression

PROSPECT clinical trial results announced

Stereotaxis showcases its remote magnetic navigation technology at TCT symposium

Everolimus-eluting stent efficient in treating native coronary artery lesions

Cardiogenesis sponsors educational symposium on refractory angina treatment method

COMPARE trial results demonstrate higher efficacy of XIENCE V stent system

SPIRIT IV trial data demonstrates superior efficacy of XIENCE V stent system

Cambridge Heart's modified Alternans technology to identify myocardial ischemia

St. Jude Medical's cardiovascular healthcare portfolio to be presented at TCT meeting

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in